Tradestie Institutional Equity Comparison Engine · Market Close Nov 16, 2026

CL vs BUD: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

BUD Wins Head-to-Head Institutional Verdict (4–2 across 6 Pillars · 7–3 Matrix Metrics)

BUD Overall Winner 6-Pillar Tally: CL 2 – 4 BUD Matrix Metrics: CL 3 – 7 BUD

As of Nov 16, 2026, Anheuser-Busch INBEV SA/NV (BUD) is the stronger overall head-to-head candidate over Colgate-Palmolive Company (CL) in the Tradestie Institutional Equity Comparison Engine, winning 7–3 core matrix metrics and 4–2 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). CL carries a Unified Composite Score of 33.9/100 (SELL) at $101.47 (24.3x Forward P/E, 20.7% operating margin), whereas BUD carries 34.9/100 (SELL) at $84.55 (17.4x Forward P/E, 26.7% operating margin).

  • Defensive Composite Rating Caution: Although BUD compares more favorably head-to-head, both CL (33.9/100 SELL) and BUD (34.9/100 SELL) currently screen in defensive SELL territory (<42/100) on our Unified Composite model.

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About CL vs BUD
CL NYSE
Colgate-Palmolive Company
Perfumes, Cosmetics & Other Toilet Preparations
$101.47
+1.81% 1D
Market Cap $77.8B
TTM Revenue $21.3B
Forward P/E 24.3x
Beta / 30D Vol -0.03β · 30% Vol
Unified Composite Score
33.9 / 100 SELL
Tech 42.0 Fund 43.0 Flow 56.0 Mom 31.1
Weinstein Technical Phase Markup · Hold / add on dips
Price above SMA50, rising 50-day trend (2.3% over 20 days), RSI 69
RSI-14: 68.8 · SMA20: $96.25 · SMA50: $91.22
BUD NYSE Head-to-Head Winner
Anheuser-Busch INBEV SA/NV
Malt Beverages
$84.55
-0.31% 1D
Market Cap $167.3B
TTM Revenue $64.0B
Forward P/E 17.4x
Beta / 30D Vol 0.23β · 33% Vol
Unified Composite Score
34.9 / 100 SELL
Tech 36.0 Fund 35.0 Flow 50.0 Mom 6.1
Weinstein Technical Phase Markup · Hold / add on dips
Price above SMA50, rising 50-day trend (2.0% over 20 days), RSI 57
RSI-14: 57.3 · SMA20: $83.31 · SMA50: $79.97

6-Pillar Scorecard Institutional Category Breakdown (CL 2 – 4 BUD)

Columns: Metric · CL · BUD
1. Valuation Multiples BUD
Forward P/E 24.3x 17.4x
Trailing P/E 38.1x 17.3x
PEG Ratio 1.79x 1.74x
EV / Revenue 3.9x 2.6x
2. Growth & Scale BUD
Revenue Growth (YoY) +4.6% +9.1%
Earnings Growth (YoY) +3.3% +52.5%
TTM Revenue (USD) $21.3B $64.0B
Market Cap $77.8B $167.3B
3. Profitability & Quality BUD
Gross Margin 60.6% 56.5%
Operating Margin 20.7% 26.7%
Net Profit Margin 9.7% 15.4%
Return on Equity (ROE) 231.7% 11.4%
4. Balance Sheet & Cash Flow BUD
Cash Generation (TTM) $3.79B $20.3B EBITDA
Cash Flow Margin 17.8% 31.7% EBITDA Mgn
Net Cash / Leverage $6.19B Net Debt (26.79x D/E) $7.92 Book/Sh · 11.4% ROE
Dividend Yield 2.14% 1.60%
5. Options & Positioning CL
Options Structure Phase SURGE UNCLASSIFIED
Current IV / %ile 24.3% (7th %ile) 23.6% (42nd %ile)
Put/Call OI Skew 0.44x (Call-Skewed) Thin ADR Chain
OBV Trend / Tech Phase NEUTRAL · Markup NEUTRAL · Markup
6. R&D & Supply-Chain Moat CL
OpEx & R&D Intensity 39.9% of Rev ($8.49B) 29.8% of Rev ($19.1B)
90D R&D Disclosures 0 papers 0 papers
Competitive Moat High-Margin Pricing Power Moat Scale & Operating Efficiency Moat
Supply-Chain Role Household & Personal Products Operator Beverages - Brewers Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: CL (3) vs BUD (7)
Institutional Metric CL BUD Criterion Row Edge
Market Capitalization
Scale
$77.8B $167.3B Larger Scale BUD
Trailing P/E Ratio
Valuation
38.1x 17.3x Lower Multiple BUD
Forward P/E Ratio
Valuation
24.3x 17.4x Lower Multiple BUD
Revenue Growth (YoY)
Growth
+4.6% +9.1% Higher Growth BUD
Operating Margin (TTM)
Profitability
20.7% 26.7% Higher Margin BUD
Net Profit Margin
Profitability
9.7% 15.4% Higher Margin BUD
Return on Equity (ROE)
Capital Efficiency
231.7% 11.4% Higher ROE CL
52-Week Range Position
Momentum
99% ($76–$102) 92% ($60–$87) Stronger Trend CL
Beta / 30D Volatility
Risk Regime
-0.03β · 30% Vol 0.23β · 33% Vol Lower Realized Risk CL
Unified Institutional Score
Composite Signal
33.9 / 100 (SELL) 34.9 / 100 (SELL) Higher Composite BUD
Trailing 12M Revenue (USD)
Operating Scale
$21.3B $64.0B FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
60.6% 56.5% Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
1.79x PEG · 3.9x EV/Rev 1.74x PEG · 2.6x EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
$3.79B ($6.19B Net Debt (26.79x D/E)) $20.3B EBITDA ($7.92 Book/Sh · 11.4% ROE) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon CL +5.45 pp
CL: +7.82% · BUD: +2.37%
3M Horizon CL +1.75 pp
CL: +10.94% · BUD: +9.19%
6M Horizon CL +8.87 pp
CL: +12.84% · BUD: +3.97%
1Y Horizon BUD +2.13 pp
CL: +28.79% · BUD: +30.92%

Financial Trajectory Operating Profitability Benchmark (Trailing 12-Month)

Split-Invariant USD Revenue & Operating Margin (%)

Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on CL vs BUD. Trailing 12-month operating profitability (CL 20.7% vs BUD 26.7%) and valuation multiples (CL 24.3x vs BUD 17.4x Forward P/E) are benchmarked directly in Pillar 4 below.

CL ADR TTM Benchmark FX-Normalized USD
TTM Revenue$21.3B
Gross Margin60.6%
Op. Margin20.7%
ROE / Fwd P/E231.7% · 24.3x
BUD ADR TTM Benchmark FX-Normalized USD
TTM Revenue$64.0B
Gross Margin56.5%
Op. Margin26.7%
ROE / Fwd P/E11.4% · 17.4x

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
CL SURGE
8d in phase · OBV NEUTRAL
Current IV 24.3%
IV Percentile 7th %ile
Put/Call OI Skew 0.44x (Call-Skewed)
IV Regime Compressed (<25th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact CL Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
BUD UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV 23.6%
IV Percentile 42nd %ile
Put/Call OI Skew Thin ADR Chain
IV Regime Balanced (25th–60th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact BUD Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
CL Moat Profile High-Margin Pricing Power Moat
Household & Personal Products Operator
Competes within the Household & Personal Products value chain with $77.8B market capitalization and 20.7% operating margin.
OpEx & R&D Reinvestment 39.9% of Rev ($8.49B)
90D Engineering Disclosures 0 Published
BUD Moat Profile Scale & Operating Efficiency Moat
Beverages - Brewers Operator
Competes within the Beverages - Brewers value chain with $167.3B market capitalization and 26.7% operating margin.
OpEx & R&D Reinvestment 29.8% of Rev ($19.1B)
90D Engineering Disclosures 0 Published

Investor FAQ CL vs BUD Key Questions & Quantitative Answers

As of Nov 16, 2026, Anheuser-Busch INBEV SA/NV (BUD) is the stronger overall head-to-head candidate over Colgate-Palmolive Company (CL) in the Tradestie Institutional Equity Comparison Engine, winning 7–3 core matrix metrics and 4–2 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). CL carries a Unified Composite Score of 33.9/100 (SELL) at $101.47 (24.3x Forward P/E, 20.7% operating margin), whereas BUD carries 34.9/100 (SELL) at $84.55 (17.4x Forward P/E, 26.7% operating margin). Defensive Composite Rating Caution: Although BUD compares more favorably head-to-head, both CL (33.9/100 SELL) and BUD (34.9/100 SELL) currently screen in defensive SELL territory (<42/100) on our Unified Composite model.

BUD leads the Growth & Scale pillar: CL posts +4.6% YoY revenue growth and +3.3% YoY earnings growth on $21.3B TTM revenue (60.6% gross margin, 20.7% operating margin), compared with BUD at +9.1% YoY revenue growth and +52.5% YoY earnings growth on $64.0B TTM revenue (56.5% gross margin, 26.7% operating margin). On trailing 12-month operating scale, CL generates $21.3B in USD-normalized revenue versus $64.0B for BUD. In operating R&D and SG&A reinvestment, CL deploys 39.9% of Rev ($8.49B) (0 90-day corporate R&D disclosures) versus 29.8% of Rev ($19.1B) (0 disclosures) for BUD.

BUD screens cheaper on headline valuation multiples. CL trades at 24.3x Forward P/E, 38.1x Trailing P/E, 1.79x PEG, and 3.9x EV/Revenue (17.8% FCF margin), whereas BUD trades at 17.4x Forward P/E, 17.3x Trailing P/E, 1.74x PEG, and 2.6x EV/Revenue (31.7% EBITDA margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against CL (231.7% ROE) versus BUD (11.4% ROE) capital efficiency.

In options market volatility and institutional positioning, CL carries 24.3% implied volatility (7th %ile, Compressed (<25th %ile)), a 0.44x (Call-Skewed) Put/Call open-interest ratio, NEUTRAL on-balance volume, and sits in a SURGE options structure phase (-0.03β · 30% Vol realized risk). By comparison, BUD carries 23.6% implied volatility (42nd %ile, Balanced (25th–60th %ile)), thin ADR options open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (0.23β · 33% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 16, 2026. For educational research only; not investment advice.